FDG-PET imaging in the management of non-small-cell lung cancer

被引：9
|
作者：
Salminen, E
Mac Manus, M
机构：
[1] Turku Univ Hosp, Dept Radiotherapy & Oncol, FIN-20520 Turku, Finland
[2] Peter MacCallum Canc Inst, Melbourne, Vic 3000, Australia
来源：
ANNALS OF ONCOLOGY | 2002年 / 13卷 / 03期
关键词：
FDG-PET; non-small-cell lung cancer; outcome; staging; treatment;
D O I：
10.1093/annonc/mdf106
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Lung cancer is currently the leading cause of cancer-related death in both men and women in most Western countries. Tumour stage is the strongest prognostic factor and the most important parameter guiding treatment decision making. Metabolic positron emission tomography imaging with fluorodeoxyglucose (FDG-PET) has consistently proved superior to conventional imaging for staging of non-small-cell lung cancer and provides information of greater prognostic significance than can be obtained using conventional approaches. FDG-PET has been approved in the USA. Germany and the UK as a basic and invaluable tool in the management of lung cancer.
引用
收藏
页码：357 / 360
页数：4
相关论文
共 50 条
  • [1] Non-small cell lung cancer: FDG-PET imaging
    Erasmus, JJ
    McAdams, HP
    Patz, EF
    JOURNAL OF THORACIC IMAGING, 1999, 14 (04) : 247 - 256
  • [2] Value of FDG-PET in the management of non-small cell lung cancer
    Stroobants, S
    Verschakelen, J
    Vansteenkiste, J
    EUROPEAN JOURNAL OF RADIOLOGY, 2003, 45 (01) : 49 - 59
  • [3] FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer
    Mitsunori Higuchi
    Yuki Owada
    Takuya Inoue
    Yuzuru Watanabe
    Takumi Yamaura
    Mitsuro Fukuhara
    Takeo Hasegawa
    Hiroyuki Suzuki
    World Journal of Surgical Oncology, 14
  • [4] Chemotherapy response evaluation with FDG-PET in patients with non-small-cell lung cancer
    de Geus-Oei, L.
    van der Heijden, H. F. M.
    Visser, E. P.
    Hermsen, R.
    van Hoorn, B. A.
    Timmer-Bonte, J. N.
    Willemsen, A. T.
    Pruim, J.
    Corstens, F. H. M.
    Krabbe, P. F. M.
    Oyen, W. J. G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 : S143 - S143
  • [5] FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer
    Higuchi, Mitsunori
    Owada, Yuki
    Inoue, Takuya
    Watanabe, Yuzuru
    Yamaura, Takumi
    Fukuhara, Mitsuro
    Hasegawa, Takeo
    Suzuki, Hiroyuki
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2016, 14
  • [6] Staging of non-small-cell lung cancer and application of FDG-PET - A cost modeling approach
    Verboom, P
    Herder, GJM
    Hoekstra, OS
    Smit, EF
    van den Bergh, JHAM
    van Velthoven, PCM
    Grijseels, EWM
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2002, 18 (03) : 576 - 585
  • [7] Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer
    Bradley, J
    Thorstad, WL
    Mutic, S
    Miller, TR
    Dehdashti, F
    Siegel, BA
    Bosch, W
    Bertrand, RJ
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 59 (01): : 78 - 86
  • [8] Comparison of FDG-PET findings of brain metastasis from non-small-cell lung cancer and small-cell lung cancer
    Lee, Ho-Young
    Chung, June-Key
    Jeong, Jae Min
    Lee, Dong Soo
    Kim, Dong Gyu
    Jung, Hee Won
    Lee, Myung Chul
    ANNALS OF NUCLEAR MEDICINE, 2008, 22 (04) : 281 - 286
  • [9] FDG-PET in addition to conventional work-up in non-small-cell lung cancer
    van Tinteren, H
    Smit, EF
    Hoekstra, OS
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (07) : 1591 - 1591
  • [10] The efficacy of FDG-PET in the management of non-small cell lung cancer.
    Trieu, TC
    Littlefield, JL
    Lowe, VJ
    JOURNAL OF NUCLEAR MEDICINE, 1997, 38 (05) : 293 - 293
12345